Share Price, page-9947

The quality of the PMS results were so good that it leads to two points. First, the animal results were consistently good in conditions chosen for having common ground underlying their pathology so that success in one would rightly lead to an increased expectation of success in the others.

Secondly, such obvious benefits in humans shown in the Phase 2 would inspire confidence in the phase 3 to come so PMS alone, whether through licencing in the short term or market sales longer term, adds huge value to Neuren above and beyond Daybue. So whilst a poor result for PH would likely drop the SP initially Neuren is still perfectly poised to grow considerably from where it sits now.